{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:02:04Z","timestamp":1792202524199,"version":"4.4.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2009,11,29]],"date-time":"2009-11-29T00:00:00Z","timestamp":1259452800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1007\/s11892-009-0076-8","type":"journal-article","created":{"date-parts":[[2009,11,28]],"date-time":"2009-11-28T05:54:01Z","timestamp":1259387641000},"page":"466-472","source":"Crossref","is-referenced-by-count":9,"title":["Management of diabetes in dialysis patients"],"prefix":"10.1007","volume":"9","author":[{"given":"Mark E.","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,11,29]]},"reference":[{"key":"76_CR1","volume-title":"USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States","author":"U.S. Renal Data Systems","year":"2008","unstructured":"U.S. Renal Data Systems: USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2008."},{"key":"76_CR2","first-page":"150","volume":"70","author":"M.E. Williams","year":"2006","unstructured":"Williams ME, Lacson E Jr, Teng M, et al.: Hemodialyzed type I and type II diabetic patients in the US: characteristics, glycemic control, and survival Kidney Intern 2006, 70:150\u20131509.","journal-title":"Hemodialyzed type I and type II diabetic patients in the US: characteristics, glycemic control, and survival Kidney Intern"},{"key":"76_CR3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1046\/j.1525-139x.2000.00007.x","volume":"13","author":"R.H. Mak","year":"2000","unstructured":"Mak RH: Impact of end-stage renal disease and dialysis on glycemic control. Semin Dial 2000, 13:4\u20138.","journal-title":"Semin Dial"},{"issue":"Suppl2","key":"76_CR4","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.2337\/dc08-s241","volume":"31","author":"L. Monnier","year":"2008","unstructured":"Monnier L, Colette C: Glycemic variability: should we and can we prevent it? Diabetes Care 2008, 31(Suppl 2):S150\u2013S154.","journal-title":"Diabetes Care"},{"key":"76_CR5","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2337\/dc06-2127","volume":"33","author":"K. Kalantar-Zadeh","year":"2007","unstructured":"Kalantar-Zadeh K, Kopple JD, Regidor DL, et al.: Hemoglobin A1c and survival in maintenance hemodialysis patients. Diabetes Care 2007, 33:1049\u20131055.","journal-title":"Diabetes Care"},{"key":"76_CR6","doi-asserted-by":"crossref","unstructured":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. Diabetes Control and Complications Trial Research Group [no authors listed]. N Engl J Med 1993, 329:977\u2013986.","DOI":"10.1056\/NEJM199309303291401"},{"key":"76_CR7","doi-asserted-by":"crossref","unstructured":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 dieter (UKPDS 33). UK Prospective Diabetes Study Group [no authors listed]. Lancet 1998, 352:837\u2013853.","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"76_CR8","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"R.R. Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, et al.: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577\u20131589.","journal-title":"N Engl J Med"},{"key":"76_CR9","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1001\/jama.2009.511","volume":"301","author":"S.E. Kahn","year":"2009","unstructured":"Kahn SE: Glucose control in type 2 diabetes: still worthwhile and worth pursuing. JAMA 2009, 301:1590\u20131592.","journal-title":"JAMA"},{"key":"76_CR10","first-page":"25","volume-title":"Renal Nutrition","author":"M. Williams","year":"2003","unstructured":"Williams M: Carbohydrate metabolism in renal failure. In Renal Nutrition, edn 2. Edited by Kopple J. Philadelphia: Lippincott, Williams, and Wilkins; 2003:25\u201339.","edition":"edn 2"},{"key":"76_CR11","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1053\/j.ajkd.2008.04.011","volume":"52","author":"C.P. Kovesdy","year":"2008","unstructured":"Kovesdy CP, Sharma K, Kalantar-Zadeh K: Glycemic control in diabetic CKD patients: where do we stand? Am J Kidney Dis 2008, 52:766\u2013777.","journal-title":"Am J Kidney Dis"},{"issue":"Suppl16","key":"76_CR12","first-page":"S102","volume":"24","author":"R.A. DeFronzo","year":"1983","unstructured":"DeFronzo RA, Smith D, Alvestrand A: Insulin action in uremia. Kidney Int 1983, 24(Suppl 16):S102\u2013S124.","journal-title":"Kidney Int"},{"key":"76_CR13","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/ki.1995.24","volume":"47","author":"A. Kautzky-Willer","year":"1995","unstructured":"Kautzky-Willer A, Pacini G, Barnas U, et al.: Intravenous calcitriol normalizes insulin sensitivity in uremic patients. Kidney Int 1995, 47:200\u2013206.","journal-title":"Kidney Int"},{"key":"76_CR14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1172\/JCI7535","volume":"105","author":"K. Cusi","year":"2000","unstructured":"Cusi K, Maezono K, Osman A, et al.: Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000, 105:311\u2013320.","journal-title":"J Clin Invest"},{"key":"76_CR15","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1046\/j.1464-5491.2003.01025.x","volume":"20","author":"G. Biesenbach","year":"2003","unstructured":"Biesenbach G, Raml A, Schmekal B, et al.: Decreased insulin requirement in relation to GFR in nephropathic type 1 and insulin-treated type 2 diabetic patients. Diabet Med 2003, 20:642\u2013645.","journal-title":"Diabet Med"},{"key":"76_CR16","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/MNH.0b013e32830fe377","volume":"17","author":"I.H. Boer de","year":"2008","unstructured":"de Boer IH: Vitamin D and glucose metabolism in chronic kidney disease. Curr Opin Nephrol Hypertens 2008, 17:566\u2013572.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"76_CR17","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2337\/dc08-1688","volume":"32","author":"S. Kazempour-Ardebili","year":"2009","unstructured":"Kazempour-Ardebili S, Lecamwasam VL, Dassonyaka T, et al.: Assessing glycemic control in maintenance hemodialysis patients with type 2 diabetes. Diabetes Care 2009, 32:1137\u20131142.","journal-title":"Diabetes Care"},{"key":"76_CR18","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM197608192950804","volume":"295","author":"R.J. Koenig","year":"1976","unstructured":"Koenig RJ, Peterson CM, Jones RL, et al.: Correlation of glucose regulation and hemoglobin A1c in diabetes mellitus. N Engl J Med 1976, 295:417\u2013420.","journal-title":"N Engl J Med"},{"key":"76_CR19","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1046\/j.1464-5491.2003.01065.x","volume":"21","author":"S.L. Jeffcoate","year":"2003","unstructured":"Jeffcoate SL: Diabetes control and complications: the role of glycated haemoglobin, 25 years on. Diabet Med 2003, 21:657\u2013665.","journal-title":"Diabet Med"},{"issue":"Suppl1","key":"76_CR20","first-page":"S2","volume":"32","author":"American Diabetes Association","year":"2009","unstructured":"American Diabetes Association: Clinical Practice Recommendations 2009. Diabetes Care 2009, 32(Suppl 1):S2\u2013S41.","journal-title":"Diabetes Care"},{"key":"76_CR21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1053\/ajkd.2003.50114","volume":"41","author":"A. Ansari","year":"2003","unstructured":"Ansari A, Thomas S, Goldsmith D: Assessing glycemic control in patients with diabetes and end-stage renal failure. Am J Kidney Dis 2003, 41:523\u2013531.","journal-title":"Am J Kidney Dis"},{"key":"76_CR22","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1464-5491.2004.01318.x","volume":"21","author":"R.I. Holt","year":"2004","unstructured":"Holt RI, Gallen I: Time to move beyond glycosylated haemoglobin. Diabet Med 2004, 21:655\u2013656.","journal-title":"Diabet Med"},{"key":"76_CR23","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/clinchem\/48.5.784","volume":"48","author":"R.R. Little","year":"2002","unstructured":"Little RR, Tennill AL, Rohfing G: Can glycohemoglobin be used to assess glycemic control in patients with chronic renal failure? Clin Chem 2002, 48:784\u2013786.","journal-title":"Clin Chem"},{"key":"76_CR24","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.diabres.2008.11.038","volume":"83","author":"E. Ishimura","year":"2009","unstructured":"Ishimura E, Okuno S, Kono K, et al.: Glycemic control and survival of diabetic hemodialysis patients: importance of lower hemoglobin A1c levels. Diabetes Res Clin Pract 2009, 83:320\u2013326.","journal-title":"Diabetes Res Clin Pract"},{"key":"76_CR25","doi-asserted-by":"crossref","first-page":"826","DOI":"10.2169\/internalmedicine.37.826","volume":"38","author":"T. Nakao","year":"1998","unstructured":"Nakao T, Matsumoto H, Okada T, et al.: Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis. Intern Med 1998, 38:826\u2013830.","journal-title":"Intern Med"},{"key":"76_CR26","first-page":"482","volume":"4","author":"T.P. Peacock","year":"2008","unstructured":"Peacock TP, Shihabi ZK, Dolbare EL, et al.: Comparison of glycated albumin and hemoglobin A1c levels in patients with chronic renal failure on hemodialysis. Nat Clin Pract Nephrol 2008, 4:482\u2013483.","journal-title":"Nat Clin Pract Nephrol"},{"key":"76_CR27","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1681\/ASN.2006070772","volume":"18","author":"M. Inaba","year":"2007","unstructured":"Inaba M, Okuno S, Kumeda Y, et al.: Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 2007, 18:896\u2013903.","journal-title":"J Am Soc Nephrol"},{"key":"76_CR28","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/clpt.1992.10","volume":"51","author":"D.E. Uehlinger","year":"1992","unstructured":"Uehlinger DE, Gotch FA, Sheiner LB: A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther 1992, 51:76\u201389.","journal-title":"Clin Pharmacol Ther"},{"key":"76_CR29","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1592\/phco.29.4.468","volume":"29","author":"J.N. Brown","year":"2009","unstructured":"Brown JN, Kemp DW, Brice KR: Class effect of erythropoietin therapy on hemoglobin A(1c) in a patient with diabetes mellitus and chronic kidney disease not undergoing hemodialysis. Pharmacotherapy 2009, 29:468\u2013472.","journal-title":"Pharmacotherapy"},{"key":"76_CR30","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/ajkd.2002.30549","volume":"39","author":"M.S. Joy","year":"2002","unstructured":"Joy MS, Cefalu WT, Hogan SL, et al.: Long-term glycemic control in diabetic patients receiving hemodialysis. Am J Kidney Dis 2002, 39:297\u2013307.","journal-title":"Am J Kidney Dis"},{"key":"76_CR31","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/sj.ki.5001886","volume":"70","author":"B. Feldt-Rasmussen","year":"2006","unstructured":"Feldt-Rasmussen B: Is there a need to optimize glycemic control in hemodialyzed diabetic patients? Kidney Int 2006, 70:1392\u20131394.","journal-title":"Kidney Int"},{"key":"76_CR32","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.2337\/dc08-0864","volume":"31","author":"E. Kilpatrick","year":"2008","unstructured":"Kilpatrick E, Rigby AS, Atkin SL: A1c variability and the risk of microvascular complications in type 1 diabetes: data from the diabetes control and complications trial. Diabetes Care 2008, 31:2198\u20132202.","journal-title":"Diabetes Care"},{"key":"76_CR33","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/ncpneph0881","volume":"4","author":"M. Abe","year":"2008","unstructured":"Abe M, Matsumoto K: Glycated hemoglobin or glycated albumin for assessment of glycemic control in hemodialysis patients with diabetes? Nat Clin Pract Nephrol 2008, 4:482\u2013483.","journal-title":"Nat Clin Pract Nephrol"},{"key":"76_CR34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1475-2840-5-27","volume":"5","author":"L.J. Pu","year":"2006","unstructured":"Pu LJ, Lu L, Xu XW, et al.: Value of serum glycated albumin and high-sensitivity C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol 2006, 5:27\u201334.","journal-title":"Cardiovasc Diabetol"},{"key":"76_CR35","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.lfs.2008.08.001","volume":"83","author":"S. Yamada","year":"2008","unstructured":"Yamada S, Inaba M, Shidara K, et al.: Association of glycated albumin, but not glycated hemoglobin, with peripheral vascular calcification in hemodialysis patients with type 2 diabetes. Life Sci 2008, 83:516\u2013519.","journal-title":"Life Sci"},{"key":"76_CR36","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2337\/diab.43.2.313","volume":"43","author":"P. Reichard","year":"1994","unstructured":"Reichard P, Pihl M: Mortality and treatment side effects during long-term intensified conventional insulin treatment in the Stockholm Diabetes Intervention study. Diabetes 1994, 43:313\u2013317.","journal-title":"Diabetes"},{"key":"76_CR37","doi-asserted-by":"crossref","unstructured":"Effects of intensive glucose lowering in type 2 diabetes. ACCORD Study Group [no authors listed]. N Engl J Med 2008, 358:2545\u20132559.","DOI":"10.1056\/NEJMoa0802743"},{"key":"76_CR38","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMicm066227","volume":"358","author":"A. Patel","year":"2008","unstructured":"Patel A, MacMahon S, Chalmers J, et al.: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. ADVANCE Collaborative Group. N Engl J Med 2008, 358:2560\u20132572.","journal-title":"N Engl J Med"},{"key":"76_CR39","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","volume":"360","author":"W. Duckworth","year":"2009","unstructured":"Duckworth W, Abraira C, Moritz T, et al.: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129\u2013139.","journal-title":"N Engl J Med"},{"key":"76_CR40","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1081\/JDI-100100866","volume":"22","author":"Y.S. Haviv","year":"2000","unstructured":"Haviv YS, Sharkia M, Safadi R: Hypoglycemic in patients with renal failure. Ren Fail 2000, 22:219\u2013223.","journal-title":"Ren Fail"},{"key":"76_CR41","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000185061","volume":"49","author":"G. Ramirez","year":"1988","unstructured":"Ramirez G, Brueggemeyer C, Ganguly A: Counterregulatory hormonal responses to insulin-induced hypoglycemia in patients on chronic hemodialysis. Nephron 1988, 49:231\u2013236.","journal-title":"Nephron"},{"key":"76_CR42","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1001\/archinte.139.1.101","volume":"139","author":"V.K. Bansal","year":"1997","unstructured":"Bansal VK, Brooks MH, York JC, et al.: Intractable hypoglycemia in a patient with renal failure. Arch Intern Med 1997, 139:101\u2013102.","journal-title":"Arch Intern Med"},{"key":"76_CR43","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0889-8529(18)30391-8","volume":"18","author":"R. Arem","year":"1989","unstructured":"Arem R: Hypoglycemia associated with renal failure. Endocrinol Metab Clin North Am 1989, 18:103\u2013121.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"76_CR44","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.2215\/CJN.00800209","volume":"4","author":"M.F. Moen","year":"2009","unstructured":"Moen MF, Zhan M, Hsu VD, et al.: Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol 2009, 4:1121\u20131127.","journal-title":"Clin J Am Soc Nephrol"},{"key":"76_CR45","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1046\/j.1525-139X.1999.t01-5-00001.x","volume":"12","author":"M.E. Williams","year":"1999","unstructured":"Williams ME, Roshan B: Role of the new hypoglycemic drugs in diabetic patients with ESRD. Semin Dial 1999, 12:25\u201331.","journal-title":"Semin Dial"},{"key":"76_CR46","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1053\/j.ajkd.2007.08.012","volume":"50","author":"N.D. Lubowski","year":"2007","unstructured":"Lubowski ND, Siegel R, Pittas AG: Management of glycemia in patients with diabetes mellitus and CKD. Am J Kidney Dis 2007, 50:865\u2013879.","journal-title":"Am J Kidney Dis"},{"key":"76_CR47","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/ndt\/gfi205","volume":"21","author":"A. Ersoy","year":"2006","unstructured":"Ersoy A, Ersoy C, Altinay T: Insulin analogue usage in a haemodialysis patient with type 2 diabetes. Nephrol Dial Transplant 2006, 21:553\u2013554.","journal-title":"Nephrol Dial Transplant"},{"issue":"2Suppl2","key":"76_CR48","first-page":"S12","volume":"49","author":"KDOQI","year":"2007","unstructured":"KDOQI: KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007, 49(2 Suppl 2):S12\u2013S154.","journal-title":"Am J Kidney Dis"},{"key":"76_CR49","doi-asserted-by":"crossref","unstructured":"Saltpeter S, Greyber E, Pasternak G, et al.: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2006, (1):CD002967.","DOI":"10.1002\/14651858.CD002967.pub2"},{"key":"76_CR50","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1001\/jama.2009.509","volume":"301","author":"D.M. Nathan","year":"2009","unstructured":"Nathan DM: Progress in diabetes research: what\u2019s next? JAMA 2009, 301:1599\u20131601.","journal-title":"JAMA"},{"key":"76_CR51","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000151276","volume":"29","author":"M.E. Williams","year":"2009","unstructured":"Williams ME, Lacson E Jr, Teng M, et al.: Extremes of glycemic control (HbA1c) increase hospitalization risk in diabetic hemodialysis patients in the US. Am J Nephrol 2009, 29:54\u201361.","journal-title":"Am J Nephrol"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-009-0076-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11892-009-0076-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-009-0076-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T23:13:00Z","timestamp":1590275580000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11892-009-0076-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,29]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["76"],"URL":"https:\/\/doi.org\/10.1007\/s11892-009-0076-8","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,29]]}}}